NASDAQ: VBIO · Life Sciences · 14 alerts · CIK 1787740
Share price
$0.5290Close, Nov 16
Market cap
$11.7M
Shares outstanding
22.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Valion Bio, Inc. filings on SEC EDGAR ↗
Interim CEO Dean Zikria released a 30-day strategic assessment focusing on advancing the Entolimod clinical pipeline and commercializing the company's Velocity Bioworks CDMO unit. The company is exploring strategic partnerships and licensing deals to bridge the gap between its scientific assets and current market valuation.
Valion Bio's subsidiary, Velocity Bioworks, successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform, achieving a milestone in their partnership. The evaluation demonstrated that NMR measurements can track microbial growth in real-time, supporting the development of non-invasive bioprocess monitoring for biologics manufacturing.
Valion Bio highlighted the capabilities of its wholly owned CDMO subsidiary, Velocity Bioworks, to support biotechnology companies seeking domestic U.S.-based manufacturing. The update follows the implementation of Section 232 pharmaceutical tariffs, positioning Velocity's San Antonio facility as a strategic option for early-phase clinical drug substance manufacturing.
Valion Bio announced the successful completion of formulation work for a novel oral mucosal version of its radiation protection biologic, Entolimod, using Shear Kershman Laboratories' BioViscid platform. This milestone creates a potential needle-free delivery pathway that could significantly expand the addressable market for radiological emergency deployment. The company plans to move into studies testing systemic delivery into the bloodstream next.